Rallybio Corporation
RLYB
$14.35
$0.322.28%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 222.00K | 212.00K | 212.00K | 212.00K | 38.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 222.00K | 212.00K | 212.00K | 212.00K | 38.00K |
| Cost of Revenue | 3.66M | 4.14M | 618.00K | 5.73M | 5.39M |
| Gross Profit | -3.43M | -3.93M | -406.00K | -5.51M | -5.35M |
| SG&A Expenses | 2.98M | 2.99M | 4.20M | 4.16M | 2.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.63M | 7.14M | 10.27M | 9.88M | 8.35M |
| Operating Income | -6.41M | -6.93M | -10.06M | -9.67M | -8.31M |
| Income Before Tax | -5.85M | 16.02M | -9.70M | -9.44M | -11.04M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.85M | 16.02M | -9.70M | -9.44M | -11.04M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.85M | 16.02M | -9.70M | -9.44M | -11.04M |
| EBIT | -6.41M | -6.93M | -10.06M | -9.67M | -8.31M |
| EBITDA | -6.41M | -6.89M | -10.03M | -9.64M | -8.28M |
| EPS Basic | -1.03 | 2.84 | -1.73 | -1.69 | -1.98 |
| Normalized Basic EPS | -0.64 | -0.72 | -1.08 | -1.05 | -0.87 |
| EPS Diluted | -1.03 | 2.84 | -1.73 | -1.69 | -1.98 |
| Normalized Diluted EPS | -0.64 | -0.72 | -1.08 | -1.05 | -0.87 |
| Average Basic Shares Outstanding | 5.68M | 5.63M | 5.61M | 5.60M | 5.58M |
| Average Diluted Shares Outstanding | 5.68M | 5.63M | 5.61M | 5.60M | 5.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |